EE426 A Comparison of the Cost-Saving Impact of Biosimilar Switching Policies across Canadian Provinces: A Case-Study for a Ranibizumab Biosimilar

This examined the impact of differing ophthalmology biosimilar switching policies on cost-savings for Canadian payors. The anticipated budget impact of a ranibizumab biosimilar was estimated across ten provincial drug plans. Resulting analysis identified possible opportunities for increased drug plan cost-savings associated with adopting proactive biosimilar switching policies.

Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: S. Keady, N. Goyert-Stephens, Q. Xin, L. Morris, M. Thomas, G. Foxon Source Type: research